NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Mary Dwyer, MS, Senior Director, Guidelines Operations, NCCN
Hema Sundar, PhD, Senior Manager, Global Clinical Content, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Andrew D. Zelenetz, MD, PhD, Panel Chair, has disclosed receiving grant/research support from Arvinas, Inc., BeiGene, Ltd. (now BeOne Medicines), Genentech, Inc., MEI Pharma, Inc., and Roche Laboratories, Inc.; receiving consulting fees from AbbVie, Inc., Amgen Inc., Arvinas, Inc., AstraZeneca Pharmaceuticals LP, BeiGene, Ltd. (now BeOne Medicines), Bristol Myers Squibb, Curio Science, DAVA Oncology, Eli Lilly and Company, Genentech, Inc., Genmab US, Inc., Gilead Sciences, Inc./Kite Pharma, Inc., Ipsen Biopharmaceuticals, Inc., MEI Pharma, Inc., and Roche Laboratories, Inc.; and serving as a scientific advisor for Arvinas, Inc. and Eli Lilly and Company.
Leo I. Gordon, MD, Panel Vice Chair, has disclosed receiving consulting fees from Ono Pharmaceutical Co., Ltd.; and receiving honoraria from Novartis Pharmaceuticals Corporation.
Julie E. Chang, MD, Panel Member, has disclosed receiving grant/research support from Celgene Corporation and Genentech, Inc.; receiving consulting fees from AbbVie, Inc.; and serving as a scientific advisor for BeiGene, Ltd., Genentech, Inc., and Ono Pharmaceutical Co., Ltd.
Beth Christian, MD, Panel Member, has disclosed receiving grant/research support from Acerta Pharma, Bristol Myers Squibb, Genentech, Inc., Kite Pharma, Inc., and Millennium Pharmaceuticals, Inc.; and receiving consulting fees from AstraZeneca Pharmaceuticals LP and Ipsen.
Thomas M. Habermann, MD, Panel Member, has disclosed receiving grant/research support from Genentech, Inc., Sorrento Therapeutics, Inc., and Vavotar Life Sciences LLC; and serving as a scientific advisor for Eli Lilly and Company and Seagen Inc.
Praveen Ramakrishnan, MD, MS, Panel Member, has disclosed receiving consulting fees from Bristol Myers Squibb and Gilead Sciences, Inc./Kite Pharma, Inc.; and serving as a scientific advisor for Acrotech Biopharma Inc., ADC Therapeutics, Bristol Myers Squibb, Ipsen Biopharmaceuticals, Inc., Gilead Sciences, Inc./Kite Pharma, Inc., and Sobi.
Stephen D. Smith, MD, Panel Member, has disclosed receiving grant/research support from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare, BeiGene, Ltd., Denovo Biopharma, Enterome, Genentech, Inc., Incyte Corporation, Kymera Therapeutics, Inc., Merck & Co., Inc., MorphoSys AG, Nanjing Pharmaceutical Co., Ltd., and Viracta Therapeutics, Inc.; and receiving consulting fees from AbbVie, Inc., ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene, Ltd., Genentech, Inc., Incyte Corporation, Karyopharm Therapeutics, Kite Pharma, Inc., Lumanity, Merck & Co., Inc., and Numab Therapeutics AG.
Joseph Tuscano, MD, Panel Member, has disclosed receiving grant/research support from AbbVie, Inc., ADC Therapeutics, Bristol Myers Squibb, Genentech, Inc., Pharmacyclics, and Seagen Inc.

View all of the conflicts of interest for the NCCN Guidelines panel 

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.